New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Study offers proof of concept for treating pediatric brain tumors with immunotherapy

Study offers proof of concept for treating pediatric brain tumors with immunotherapy

by Children’s Hospital of PhiladelphiaGPC2 is expressed in pediatric brain tumors. (A) GPC2 RNA sequencing data across OpenPBTA pediatric brain tumors cohorts. Neuroblastoma GPC2 RNA sequencing includ
Oncology February 20,2024
Study offers proof of concept for treating pediatric brain tumors with immunotherapy

Study offers proof of concept for treating pediatric brain tumors with immunotherapy

by Children’s Hospital of PhiladelphiaGPC2 is expressed in pediatric brain tumors. (A) GPC2 RNA sequencing data across OpenPBTA pediatric brain tumors cohorts. Neuroblastoma GPC2 RNA sequencing includ
Oncology February 20,2024
Researchers develop priorities for interventions to address health disparities in lung nodule management

Researchers develop priorities for interventions to address health disparities in lung nodule management

by Boston University School of MedicineCascade-of-care framework for identifying potential areas for intervention to reduce disparities in lung nodule evaluation. This figure shows each step of a
Oncology February 20,2024
Researchers develop priorities for interventions to address health disparities in lung nodule management

Researchers develop priorities for interventions to address health disparities in lung nodule management

by Boston University School of MedicineCascade-of-care framework for identifying potential areas for intervention to reduce disparities in lung nodule evaluation. This figure shows each step of a
Oncology February 20,2024
Researchers link ovarian cancer to bacteria colonization in microbiome

Researchers link ovarian cancer to bacteria colonization in microbiome

by Susan Murphy,Mayo Clinicβ-diversities measures were compared. For β-diversity, Bray–Curtis (BC), unweighted, and weighted, UniFrac distance metrics were reported. The most significant metric
Oncology February 20,2024
Researchers link ovarian cancer to bacteria colonization in microbiome

Researchers link ovarian cancer to bacteria colonization in microbiome

by Susan Murphy,Mayo Clinicβ-diversities measures were compared. For β-diversity, Bray–Curtis (BC), unweighted, and weighted, UniFrac distance metrics were reported. The most significant metric
Oncology February 20,2024
Researchers identify feature of early stage colorectal cancer tumors that signals aggressiveness

Researchers identify feature of early stage colorectal cancer tumors that signals aggressiveness

by Cheryl Critchley,Monash UniversityOncogenic KRAS-driven MAPK signaling confers tolerance to epithelial TGFβ activation. a Representative H&E and Alk5 ISH of small intestinal tissue from V
Oncology February 20,2024
Researchers identify feature of early stage colorectal cancer tumors that signals aggressiveness

Researchers identify feature of early stage colorectal cancer tumors that signals aggressiveness

by Cheryl Critchley,Monash UniversityOncogenic KRAS-driven MAPK signaling confers tolerance to epithelial TGFβ activation. a Representative H&E and Alk5 ISH of small intestinal tissue from V
Oncology February 20,2024
Remote dietary intervention feasible, may reduce chronic fatigue for lymphoma survivors

Remote dietary intervention feasible, may reduce chronic fatigue for lymphoma survivors

by Ohio State University Medical CenterRegistered dietitian Anna Maria Bittoni meets virtually with a cancer survivor to explain the benefits of different foods. The pilot study at The Ohio State
Oncology February 20,2024
Remote dietary intervention feasible, may reduce chronic fatigue for lymphoma survivors

Remote dietary intervention feasible, may reduce chronic fatigue for lymphoma survivors

by Ohio State University Medical CenterRegistered dietitian Anna Maria Bittoni meets virtually with a cancer survivor to explain the benefits of different foods. The pilot study at The Ohio State
Oncology February 20,2024
Study shows potential for new radiopharmaceutical cancer treatment

Study shows potential for new radiopharmaceutical cancer treatment

by Elizabeth Chapin,University of KentuckyGastrin- releasing peptide receptor (GRPR) immunoreactivity in uterine cervix cancer. Hematoxylin and eosin (H&E) staining of uterine cervix cancer
Oncology February 20,2024
Study shows potential for new radiopharmaceutical cancer treatment

Study shows potential for new radiopharmaceutical cancer treatment

by Elizabeth Chapin,University of KentuckyGastrin- releasing peptide receptor (GRPR) immunoreactivity in uterine cervix cancer. Hematoxylin and eosin (H&E) staining of uterine cervix cancer
Oncology February 20,2024
Study shows promising results for immunotherapy targeting skin cancer

Study shows promising results for immunotherapy targeting skin cancer

by King's College LondonCSPG4 expression in malignant melanoma and normal tissues.aCSPG4 mRNA expression, derived from RNAseq data, across cell lines of different cancer cell type
Oncology February 20,2024
Study shows promising results for immunotherapy targeting skin cancer

Study shows promising results for immunotherapy targeting skin cancer

by King's College LondonCSPG4 expression in malignant melanoma and normal tissues.aCSPG4 mRNA expression, derived from RNAseq data, across cell lines of different cancer cell type
Oncology February 20,2024
Travel time for breast cancer screening remains long for many women in the US, new study shows

Travel time for breast cancer screening remains long for many women in the US, new study shows

by American Cancer SocietyA new study led by researchers at the American Cancer Society shows travel time to the nearest mammography facility is long for a considerable proportion of women in the
Oncology February 20,2024
Travel time for breast cancer screening remains long for many women in the US, new study shows

Travel time for breast cancer screening remains long for many women in the US, new study shows

by American Cancer SocietyA new study led by researchers at the American Cancer Society shows travel time to the nearest mammography facility is long for a considerable proportion of women in the
Oncology February 20,2024
Study examines Kentucky cancer survivors' increased risk of cancer incidence

Study examines Kentucky cancer survivors' increased risk of cancer incidence

by Elizabeth Chapin,University of KentuckyCredit: Unsplash/CC0 Public DomainWhile cancer survivors have an increased risk of developing cancer in the future, that risk is notably higher in Kentu
Oncology February 20,2024
Study examines Kentucky cancer survivors' increased risk of cancer incidence

Study examines Kentucky cancer survivors' increased risk of cancer incidence

by Elizabeth Chapin,University of KentuckyCredit: Unsplash/CC0 Public DomainWhile cancer survivors have an increased risk of developing cancer in the future, that risk is notably higher in Kentu
Oncology February 20,2024
Researchers identify protein with DYRK1A-inhibiting effect that may have implications for Down syndrome

Researchers identify protein with DYRK1A-inhibiting effect that may have implications for Down syndrome

by Kyoto UniversityDYRK1A bound to FAM53C in the cytoplasm is less active. DYRK1A not bound to FAM53C in the nucleus is highly active. Functional abnormalities cause various neuropsychiatric deve
Oncology February 20,2024
Researchers identify protein with DYRK1A-inhibiting effect that may have implications for Down syndrome

Researchers identify protein with DYRK1A-inhibiting effect that may have implications for Down syndrome

by Kyoto UniversityDYRK1A bound to FAM53C in the cytoplasm is less active. DYRK1A not bound to FAM53C in the nucleus is highly active. Functional abnormalities cause various neuropsychiatric deve
Oncology February 20,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com